Emerging targeted treatments for malignant glioma

Expert Opinion on Emerging Drugs

Volumn 10, Issue 4, 2005, Pages 845-854

  Mulholland, Paul J ^a   Thirlwell, Christina ^a   Brock, Cathryn S ^a   Newlands, Edward S ^a  

^a CHARING CROSS HOSPITAL   (United Kingdom)

Author keywords

EGFR; Glioma; MDM2; p53; PDGFR; VEGF

Indexed keywords

ADENOVIRUS VECTOR; AEE 778; ANTICONVULSIVE AGENT; ANTISENSE OLIGONUCLEOTIDE; CARMUSTINE; CILENGITIDE; CISPLATIN; ERLOTINIB; EVEROLIMUS; FLUOROURACIL; GEFITINIB; HYDROXYUREA; IMATINIB; IRINOTECAN; LAPATINIB; LOMUSTINE; LONAFARNIB; PACLITAXEL; PROCARBAZINE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN P53; PROTEIN TYROSINE KINASE INHIBITOR; RAPAMYCIN; RECOMBINANT PROTEIN; SORAFENIB; TEMOZOLOMIDE; TEMSIROLIMUS; TIPIFARNIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VATALANIB; VINCRISTINE;

BLOOD BRAIN BARRIER; BLOOD CEREBROSPINAL FLUID BARRIER; CANCER SURVIVAL; CELL CYCLE; CLINICAL RESEARCH; CLINICAL TRIAL; CYTOTOXICITY; GENE TARGETING; GENETIC TRANSFECTION; GLIOBLASTOMA; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PROTEIN TARGETING; RECOMBINANT GENE; REVIEW; TREATMENT OUTCOME; TUMOR GROWTH; TUMOR SUPPRESSOR GENE;

ANIMALS; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CLINICAL TRIALS; DRUG DELIVERY SYSTEMS; DRUGS, INVESTIGATIONAL; GLIOMA; HUMANS;

EID: 27844544655     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.10.4.845     Document Type: Review

References (55)

1. KLEIHUES P, CAVANEE WK: World Health Organization classification of tumours of the nervous system. Lyon, France (2000).
2. STEWART LA: Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet (2002) 359(9311):1011-1018.
3. CBTRUS: Statistical Report. Primary Brain Tumors in the United States, 2004-2005.
4. YUNG WK, PRADOS MD, YAYA-TUR R et al.: Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J. Clin. Oncol. (1999) 17(9):2762-2771.
5. YUNG WK: Temozolomide in malignant gliomas. Semin. Oncol. (2000) 27(3 Suppl. 6):27-34.
6. GILBERT MR, FRIEDMAN HS, KUTTESCH JF et al.: A Phase II study of temozolomide in patients with newly diagnosed supratentorial malignant glioma before radiation therapy. Neuro-oncol. (2002) 4(4):261-267.
7. DINNES J, CAVE C, HUANG S, MILNE R: A rapid and systematic review of the effectiveness of temozolomide for the treatment of recurrent malignant glioma. Br. J. Cancer (2002) 86(4):501-505.
8. ANTONADOU D, PARASKEVAIDIS M, SARRIS G et al.: Phase II randomized trial of temozolomide and concurrent radiotherapy in patients with brain metastases. J. Clin. Oncol. (2002) 20(17):3644-3650.
9. STUPP R, DIETRICH PY, OSTERMANN KRALJEVIC S et al.: Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J. Clin. Oncol. (2002) 20(5):1375-1382.
10. STUPP R, MASON WP, VAN DEN BENT MJ et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. (2005) 352(10):987-996.
11. ATHANASSIOU H, SYNODINOU M, MARAGOUDAKIS E et al.: Randomized Phase II study of temozolomide and radiotherapy compared with radiotherapy alone in newly diagnosed glioblastoma multiforme. J. Clin. Oncol. (2005) 23(10):2372-2377.
12. BREDEL M, ZENTNER J: Brain-tumour drug resistance: the bare essentials. Lancet Oncol. (2002) 3(7):397-406.
13. BREDEL M, BREDEL C, SIKIC BI: Genomics-based hypothesis generation: a novel approach to unravelling drug resistance in brain tumours? Lancet Oncol. (2004) 5(2):89-100.
14. LANG FF, BRUNER JM, FULLER GN et al.: Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: biological and clinical results. J. Clin. Oncol. (2003)21(13):2508-2518.
15. LI H, ALONSO-VANEGAS M, COLICOS MA et al.: Intracerebral adenovirus-mediated p53 tumor suppressor gene therapy for experimental human glioma. Clin. Cancer Res. (1999) 5(3):637-642.
16. LOHRUM MA, LUDWIG RL, KUBBUTAT MH, HANLON M, VOUSDEN KH: Regulation of HDM2 activity by the ribosomal protein L11. Cancer Cell. (2003) 3(6):577-587.
17. VASSILEV LT,VU BT, GRAVES B et al.: In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science (2004) 303(5659):844-848.
18. PRASAD G, WANG H, AGRAWAL S, ZHANG R: Antisense anti-MDM2 oligonucleotides as a novel approach to the treatment of glioblastoma multiforme. Anticancer Res. (2002) 22(1A):107-116.
19. ROBINSON DR, WU YM, LIN SF: The protein tyrosine kinase family of the human genome. Oncogene (2000) 19(49):5548-5557.
20. SHINOJIMA N, TADA K, SHIRAISHI S et al.: Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. Cancer Res. (2003) 63(20):6962-6970.
21. FUJIWARA K, KIURA K, UEOKA H, TABATA M, HAMASAKI S, TANIMOTO M: Dramatic effect of ZD1839 ('Iressa') in a patient with advanced non-small-cell lung cancer and poor performance status. Lung Cancer (2003) 40(1):73-76.
22. RICH JN, REARDON DA, PEERY T et al.: Phase II trial of gefitinib in recurrent glioblastoma. J. Clin. Oncol. (2004) 22(1):133-142.
23. HALATSCH ME, GEHRKE EE, VOUGIOUKAS VI et al.: Inverse correlation of epidermal growth factor receptor messenger RNA induction and suppression of anchorage-independent growth by OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in glioblastoma multiforme cell lines. J. Neurosurg. (2004) 100(3):523-533.
24. GOUDAR RK, SHI Q, HJELMELAND MD et al.: Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition. Mol. Cancer Ther. (2005) 4(1):101-112.
25. DRUKER BJ, SAWYERS CL, KANTARJIAN H et al.: Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N. Engl. J. Med. (2001) 344(14):1038-1042.
26. DRUKER BJ, TALPAZ M, RESTA DJ et al.: Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. (2001) 344(14):1031-1037.
27. KILIC T, ALBERTA JA, ZDUNEK PR et al.: Intracranial inhibition of platelet-derived growth factor-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenylaminopyrimidine class. Cancer Res. (2000) 60(18):5143-5150.
28. FRIEDMAN HS, QUINN JA, RICH JN et al.: Efficacy of imatinib mesylate plus hydroxyurea regimen in the treatment of recurrent malignant glioma: Phase II study results. J. Clin. Oncol. Proc. Am. Soc. Clin. Oncol. (2005) 24:1515a.
29. CHAUDHRY IH, O'DONOVAN DG, BRENCHLEY PE, REID H, ROBERTS IS: Vascular endothelial growth factor expression correlates with tumour grade and vascularity in gliomas. Histopathology (2001) 39(4):409-415.
30. CHENG SY, HUANG HJ, NAGANE M et al.: Suppression of glioblastoma angiogenicity and tumorigenicity by inhibition of endogenous expression of vascular endothelial growth factor. Proc. Natl. Acad. Sci. USA (1996) 93(16):8502-8507.
31. STEFANIK DF, FELLOWS WK, RIZKALLA LR et al.: Monoclonal antibodies to vascular endothelial growth factor (VEGF) and the VEGF receptor, FLT-1, inhibit the growth of C6 glioma in a mouse xenograft. J. Neuro-oncol. (2001) 55(2):91-100.
32. WOOD JM, BOLD G, BUCHDUNGER E et al.: PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res. (2000) 60(8):2178-2189.
33. REARDON DA, FRIEDMAN HS, YUNG WK et al.: A phase I/II trial of PTK787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor, in combination with either temozolomide or lomustine for patients with recurrent glioblastome multiforme (GBM). J. Clin. Oncol. Proc. Am. Soc. Clin. Oncol. (2004) 22:1513a.
34. GOLDBRUNNER RH, BENDSZUS M, WOOD J, KIDERLEN M, SASAKI M, TONN JC: PTK787/ZK222584, an inhibitor of vascular endothelial growth factor receptor tyrosine kinases, decreases glioma growth and vascularization. Neurosurgery (2004) 55(2):426-432; discussion 432.
35. SAKATA K, KATO S, FOX JC, SHIGEMORI M, MORIMATSU M: Autocrine signaling through Ras regulates cell survival activity in human glioma cells: potential cross-talk between Ras and the phosphatidylinositol 3-kinase-Akt pathway. J. Neuropathol. Exp. Neurol. (2002) 61(11):975-983.
36. HOWE LR, LEEVERS SJ, GOMEZ N, NAKIELNY S, COHEN P, MARSHALL CJ: Activation of the MAP kinase pathway by the protein kinase raf. Cell (1992) 71(2):335-342.
37. XIA W, MULLIN RJ, KEITH BR et al.: Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways. Oncogene (2002) 21(41):6255-6263.
38. SPECTOR NL, XIA W, BURRIS H 3rd et al.: Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies. J. Clin. Oncol. (2005) 23(11):2502-2512.
39. ESHLEMAN JS, CARLSON BL, MLADEK AC, KASTNER BD, SHIDE KL, SARKARIA JN: Inhibition of the mammalian target of rapamycin sensitizes U87 xenografts to fractionated radiation therapy. Cancer Res. (2002) 62(24):7291-7297.
40. RICH JN, REARDON DA, QUINN JA et al.: A phase I trial of gefitinib (ZD1839) plus rapamycin for patients with recurrent malignant glioma. J. Clin. Oncol. Proc. Am. Soc. Clin. Oncol. (2005) 23:1565a.
41. DAS A, BADRUDDOJA M, TRYCIECKY D, YU J, BLACK K: Phase I study of gefitinib and rapamycin in patients with recurrent or progressive glioblastoma (GBM). J. Clin. Oncol. Proc. Am. Soc. Clin. Oncol. (2005) 23:1572a.
42. CHANG SM, KUHN J, WEN P et al.: Phase I/pharmacokinetic study of CCI-779 in patients with recurrent malignant glioma on enzyme-inducing antiepileptic drugs. Invest. New Drugs (2004) 22(4):427-435.
43. BEUVINK I, BOULAY A, FUMAGALLI S et al.: The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation. Cell (2005) 120(6):747-759.
44. MANNE V, ROBERTS D, TOBIN A et al.: Identification and preliminary characterization of protein-cysteine farnesyltransferase. Proc. Natl. Acad. Sci. USA (1990) 87(19):7541-7545.
45. GLASS TL, LIU TJ, YUNG WK: Inhibition of cell growth in human glioblastoma cell lines by farnesyltransferase inhibitor SCH66336. Neuro-oncol. (2000) 2(3):151-158.
46. FELDKAMP MM, LALA P, LAU N, RONCARI L, GUHA A: Expression of activated epidermal growth factor receptors, Ras-guanosine triphosphate, and mitogen-activated protein kinase in human glioblastoma multiforme specimens. Neurosurgery (1999) 45(6):1442-1453.
47. WANG E, CASCIANO CN, CLEMENT RP, JOHNSON WW: The farnesyl protein transferase inhibitor SCH66336 is a potent inhibitor of MDR1 product P-glycoprotein. Cancer Res. (2001) 61(20):7525-7529.
48. DELMAS C, END D, ROCHAIX P, FAVRE G, TOULAS C, COHEN-JONATHAN E: The farnesyltransferase inhibitor R115777 reduces hypoxia and matrix metalloproteinase 2 expression in human glioma xenograft. Clin. Cancer Res. (2003) 9(16 Pt 1):6062-6068.
49. STRUMBERG D, RICHLY H, HILGER RA et al.: Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J. Clin. Oncol. (2005) 23(5):965-972.
50. NAGANUMA H, SATOH E, ASAHARA T et al.: Quantification of thrombospondin-1 secretion and expression of alphavbeta3 and alpha3beta1 integrins and syndecan-1 as cell-surface receptors for thrombospondin-1 in malignant glioma cells. J. Neuro-oncol. (2004) 70(3):309-317.
51. 5 in patients with advanced solid tumours. Eur. J. Cancer (2003) 39(7):917-926.
52. MAHER EA, FURNARI FB, BACHOO RM et al.: Malignant glioma: genetics and biology of a grave matter. Genes Dev. (2001) 15(11):1311-1333.
53. DAVIES DC: Blood-brain barrier breakdown in septic encephalopathy and brain tumours. J. Anat. (2002) 200(6):639-646.
54. DEMPSEY MF, CONDON BR, HADLEY DM: Measurement of tumor "size" in recurrent malignant glioma: 1D, 2D, or 3D? AJNR Am. J. Neuroradiol. (2005) 26(4):770-776.
55. SCHATZKIN A, GAIL M: The promise and peril of surrogate end points in cancer research. Nat. Rev. Cancer (2002) 2(1):19-27.